1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cardiovascular conditions
  5. Heart failure

Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction

Technology appraisal guidance [TA902] Published: 21 June 2023

  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

History

A list of downloadable documents created during development.

Expected publication

  • Register of interests PDF 152 KB 21 June 2023  
  • Equality Impact Assessment (Guidance development) PDF 140 KB 21 June 2023  

Final draft guidance

  • Final draft guidance  
  • Final appraisal document PDF 301 KB 18 May 2023  
  • Committee papers PDF 3.14 MB 18 May 2023  
  • Public committee slides PDF 1.62 MB 18 May 2023  
  • Final appraisal document : Equality Impact Assessment PDF 140 KB 18 May 2023  

Draft guidance

  • Draft guidance  
  • Appraisal consultation document (PDF version) PDF 304 KB 08 February 2023  
  • Committee papers PDF 7.67 MB 08 February 2023  
  • Public committee slides PDF 1.51 MB 08 February 2023  
  • Appraisal consultation document (online commenting)  
  • Appraisal consultation document (PDF version) Equality Impact Assessment (EIA) PDF 155 KB 08 February 2023  

Invitation to participate

  • Final scope PDF 179 KB 12 July 2022  
  • Final stakeholder list PDF 164 KB 12 July 2022  
  • NICE's response to comments on the draft scope and provisional stakeholder list PDF 246 KB 12 July 2022  
  • Equality impact assessment (Scoping) PDF 133 KB 12 July 2022  

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

  • Draft scope post referral PDF 196 KB 26 January 2022  
  • Draft matrix post referral PDF 164 KB 26 January 2022